Clinical Trial Update: Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) [Phase 3]

View source ↗

Summary

A phase 3 switch study evaluating the safety and efficacy of FTC/RPV/TAF fixed-dose combination in virologically suppressed adults on FTC/RPV/TDF.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Emtricitabine/Rilpivirine/Tenofovir alafenamide fixed-dose combination (emtricitabine rilpivirine tenofovir alafenamide)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV-1 Infection | Phase 3 | Status: COMPLETED | Results posted: 2017-12-08